<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851925</url>
  </required_header>
  <id_info>
    <org_study_id>EK2451/2020</org_study_id>
    <nct_id>NCT04851925</nct_id>
  </id_info>
  <brief_title>MR Fingerprinting for Vestibular Schwannomas</brief_title>
  <official_title>MR-Fingerprinting for the Prediction of the Response of Vestibular Schwannomas to Gamma Knife Radiosurgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MR Fingerprinting (MRF) will be performed in patients who will be treated with Gamma Knife&#xD;
      radio surgery for a vestibular schwannoma before the intervention. Fifty patients will be&#xD;
      included with a vestibular schwannoma of minimum 1cm in size. During follow-up, response of&#xD;
      the tumor to radiosurgery will be evaluated for each patient with MRI. The aim of the study&#xD;
      is to find patterns of vestibular schwannomas in MRF data which correlate with the type of&#xD;
      response to radio surgery, i.e. tumor control after radiosurgery, further tumor growth&#xD;
      despite radiosurgery, cystic transformation after radiosurgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">February 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor control</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients without further growth of the tumor on follow-up MRI after radiosurgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor growth</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients with growth of the tumor on follow-up MRI after radiosurgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystic transformation</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients with cystic transformation of the tumor on follow-up MRI after radiosurgery</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR Fingerprinting</intervention_name>
    <description>Specific Magnetic Resonance Imaging protocol</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with vestibular schwannoma of minimum 1cm, who will undergo Gamma Knife&#xD;
        radiosurgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Planned Gamma Knife radiosurgery for vestibular schwannoma of minimum&#xD;
        1cm in size -&#xD;
&#xD;
        Exclusion Criteria: Vestibular Schwannoma of less than 1cm in size. Other a priori&#xD;
        treatment than Gamma Knife radiosurgery&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Josa Frischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorian Hirschmann, MD</last_name>
    <phone>+4314040025780</phone>
    <email>dorian.hirschmann@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josa Frischer, MD</last_name>
    <phone>+4314040045500</phone>
    <email>josa.frischer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josa Frischer, MD</last_name>
      <phone>+4314040045500</phone>
      <email>josa.frischer@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Dorian Hirschmann, MD</last_name>
      <phone>+4314040025780</phone>
      <email>dorian.hirschmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Dorian Hirschmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josa M Frischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilbert Hangel, DI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte Gatterbauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Cho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Josa M Frischer, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

